论文部分内容阅读
目的探讨氨溴特罗联合孟鲁司特对儿童咳嗽变异性哮喘的治疗效果。方法选择2013年3月—2015年2月来本院治疗的87例咳嗽变异性哮喘患儿作为研究对象,随机分为治疗组(44例)和对照组(43例),对照组患儿给予氨溴特罗治疗,治疗组患儿给予氨溴特罗联合孟鲁司特治疗,疗程为14 d,评价两组患儿的疗效,并进行哮喘控制测试(childhood asthma control test,C-ACT)评分和肺功能(PEF变异率)检测。计量资料比较采用t检验,计数资料比较采用χ2检验,P<0.05为差异有统计学意义。结果治疗组患儿治疗总有效率(42例,95.45%)高于对照组(33例,76.74%),差异有统计学意义(P<0.05);治疗后,治疗组患儿C-ACT评分明显升高,为(23.02±2.93)分;PEF变异率明显降低,为(15.16±2.56)%,同时治疗组患儿上述指标的改善程度均优于对照组[(19.62±3.12)分、(20.93±3.88)%],差异均有统计学意义(均P<0.05)。结论氨溴特罗联合孟鲁司特治疗儿童咳嗽变异性哮喘疾病,可有效降低患儿呼吸道高反应性并改善肺功能,提高治疗效果。
Objective To investigate the therapeutic effect of ambroxol combined with montelukast on children with cough variant asthma. Methods Eighty-seven children with cough variant asthma treated in our hospital from March 2013 to February 2015 were randomly divided into treatment group (44 cases) and control group (43 cases), control group Ambroxol treatment, children in treatment group were treated with ambroxol combined with montelukast, the course of treatment was 14 days, and the efficacy of the two groups were evaluated, and asthma control test (C-ACT) Score and lung function (PEF mutation rate) test. Measurement data were compared using t test, count data were compared using χ2 test, P <0.05 for the difference was statistically significant. Results The total effective rate of treatment group (42 cases, 95.45%) was higher than that of control group (33 cases, 76.74%), the difference was statistically significant (P0.05). After treatment, C-ACT score (23.02 ± 2.93) points, the PEF mutation rate was significantly lower (15.16 ± 2.56)%, while the improvement rate of the above parameters in the treatment group was better than that in the control group (19.62 ± 3.12), ( 20.93 ± 3.88)%], the difference was statistically significant (all P <0.05). Conclusion Combined use of ambroxil and montelukast in the treatment of children with cough variant asthma can effectively reduce the airway hyperresponsiveness, improve lung function and improve the therapeutic effect in children.